31 October 2023 - Prostate cancer drug Xtandi (enzalutamide), in combination with androgen deprivation therapy to treat patients with metastatic hormone sensitive prostate cancer, will see its reimbursement status change from selective to essential starting next month.

After winning approval for treating metastatic castration resistant prostate cancer in 2013, Xtandi was also approved to treat high-risk, non-metastatic castration-resistant prostate cancer. In September 2021, an indication was added to treat all patients with metastatic hormone sensitive prostate cancer, allowing the drug to be used in all stages after recurrence.

Read Korea Biomedical Review article